Annals of Phlebology

Table. 2.

Demographic and treatment characteristics between PA and nPA group in propensity score matched adjusted data

nPA, n=201 PA, n=201 p
Age, years 56.4±14.1 56.6±14.6 NS
Male sex: no. (%) 96 (47.8%) 106 (52.7%) NS
Calf circumference 36.2±3.3 36.6±3.2 NS
GSV size (mean) 4.87±2.5 5.2±2.2 NS
Recurrence 6 (3.0%) 11 (5.5%) NS
Calf circumference 36.40±3.2 36.37±3.0 NS
Diabetes 22 (10.9%) 8 (7.0%) NS
PAOD 3 (1.5%) 3 (1.5%) NS
Combined SSV treatment 93 (46.3%) 79 (39.3%) NS
No. Of CVD related complication* 64 (31.8%) 66 (32.8%) NS
Main Endovenous Procedure
VenaSealTM 8 (4%) 10 (5.0%) NS
RFA 66 (32.8%) 76 (37.8%) NS
EVLT 108 (53.7%) 98 (48.8%) NS
UGFS 19 (9.5%) 17 (8.5%) NS
No. Of phlebectomy 3.54±2.3 3.68±2.40 NS
CEAP clinical class
0 13 (6.5%) 8 (4.0%) NS
1 2 (1.0%) 8 (4.0%)
2 132 (65.7%) 132 (65.7%)
3 31 (15.4%) 19 (9.5%)
4 23 (11.4%) 33 (16.4%)
5 0 (0.0) 1 (0.5%)

*Bleeding, thrombosis, pigmentation, lipodermatosclerosis, static ulcer, painkiller medication, deep vein thrombosis, eczema.

GSV: Great Saphenous Vein, SSV: Small Saphenous Vein, PAOD: Peripheral Arterial Occlusive Disease, CVD: Chronic Venous Disease, RFA: RadioFrequency Ablation, EVLT: EndoVenous Laser Ablation, UGFS: Ultrasonography Guided Foam Sclerotherapy.

Ann Phlebology 2022;20:30~36 https://doi.org/10.37923/phle.2022.20.1.30
© Ann Phlebology